Roche says it has no plans to scrap product lines after Boehringer Mannheim acquisition
This article was originally published in Clinica
Executive Summary
Roche Diagnostics claims it has no plans to discontinue any product lines after its acquisition of Boehringer Mannheim. The two companies' products matched extremely well, Jean-Luc Belingard, managing director of diagnostics, told Clinica. He said the new company's product range would offer "depth and breadth of technology".